AnGes Inc
TSE:4563
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
AnGes Inc
Current Portion of Long-Term Debt
AnGes Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AnGes Inc
TSE:4563
|
Current Portion of Long-Term Debt
¥54.4m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
SanBio Co Ltd
TSE:4592
|
Current Portion of Long-Term Debt
¥196m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
GNI Group Ltd
TSE:2160
|
Current Portion of Long-Term Debt
¥1B
|
CAGR 3-Years
79%
|
CAGR 5-Years
3%
|
CAGR 10-Years
17%
|
|
|
PeptiDream Inc
TSE:4587
|
Current Portion of Long-Term Debt
¥17B
|
CAGR 3-Years
98%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Takara Bio Inc
TSE:4974
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Current Portion of Long-Term Debt
¥193.6m
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
6%
|
|
AnGes Inc
Glance View
AnGes, Inc. engages in the research and development of gene-based medical products. The company is headquartered in Ibaraki-Shi, Osaka-Fu and currently employs 131 full-time employees. The company went IPO on 2002-09-25. The firm is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.
See Also
What is AnGes Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
54.4m
JPY
Based on the financial report for Dec 31, 2025, AnGes Inc's Current Portion of Long-Term Debt amounts to 54.4m JPY.
What is AnGes Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
-30%
Over the last year, the Current Portion of Long-Term Debt growth was -67%. The average annual Current Portion of Long-Term Debt growth rates for AnGes Inc have been -30% over the past three years .
